We included patients older than 18 years with previously untreated metastatic colorectal cancer , with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine , oxaliplatin , and bevacizumab ( CAPOX-B ) , WHO performance status of 0 or 1 , and adequate bone marrow , liver , and renal function .